AdvanCell Raises $315M for Targeted Alpha Therapy

AdvanCell has successfully concluded a substantial US $315 million Series D funding round, an oversubscribed event that underscores significant investor confidence in its targeted alpha therapy platform. This capital infusion is earmarked to propel its lead candidate, ADVC001, through pivotal Phase 3 trials for metastatic prostate cancer and bolster its integrated radiopharmaceutical manufacturing capabilities.

The financing round saw robust participation from a distinguished group of new and existing backers. Leading the charge was Ally Bridge Group, with Alpha Wave co-leading the investment. Significant contributions also came from prominent new investors including Bain Capital Life Sciences, Fidelity Management & Research Company, funds managed by T. Rowe Price Associates, Inc., a notable sovereign wealth fund, Eventide Asset Management, and Velosity Capital. A strong contingent of existing shareholders, including Morningside, Eli Lilly and Company, SV Health Investors, Sanofi Ventures, Abingworth, SymBiosis, Tenmile, Brandon Capital, Piper Heartland, Catalio Capital Management, Proto Axiom, and Time BioVentures, also reinvested, demonstrating sustained belief in the company's vision.

This substantial funding addresses a critical bottleneck in the burgeoning field of targeted alpha therapies: reliable isotope supply and scalable manufacturing. AdvanCell has strategically developed a proprietary, vertically integrated platform centered on Lead-212 technology. This approach aims to ensure a secure supply chain, streamline automated production, and enable scalable manufacturing, thereby accelerating the development and eventual commercialization of advanced radioligand treatments.

The strategic allocation of these funds will be multifaceted. A primary objective is to advance ADVC001, a novel Lead-212 PSMA-targeted radioligand therapy, towards registrational Phase 3 studies. Concurrently, the company will expand its proprietary Lead-212 platform, reinforcing its isotope sourcing and significantly enhancing its U.S.-based manufacturing infrastructure. This expansion is crucial for supporting not only the upcoming Phase 3 trials but also anticipated future commercial demand, positioning AdvanCell for sustained growth.

“This financing represents a pivotal moment for AdvanCell, validating our innovative Lead-212 platform and the immense potential of ADVC001,” stated Philina Lee, Ph.D., Chief Executive Officer. “With this capital, we are well-equipped to enter our next growth phase, driving ADVC001 towards pivotal development, securing our supply chain, and expanding our manufacturing capacity. This will also accelerate our pipeline of targeted alpha therapies, bringing us closer to delivering on the promise of this treatment modality for a wider range of cancer patients.”

The targeted alpha therapy market is experiencing rapid evolution, with companies that master both differentiated therapeutic assets and end-to-end operational control expected to lead. AdvanCell's integrated model, coupled with its de-risked lead program and experienced leadership, positions it favorably to capture significant market share. The addition of Andrew Lam from Ally Bridge Group and Nik Economopoulos from Alpha Wave to the Board of Directors further strengthens the company's strategic oversight.

AdvanCell's lead candidate, ADVC001, is currently in Phase 2 trials for metastatic prostate cancer. Its design focuses on delivering potent alpha radiation directly to tumor cells while minimizing collateral damage to healthy tissues. Early clinical data has shown encouraging anti-tumor activity and favorable tolerability, supporting the platform's potential and paving the way for broader applications across various oncology indications.